Lab (Specimen)

Conventional Units

SI Units
17-Ketogenic steroids (urine)
top of page 		Male:  5 – 23 mg/day
Female: 3 – 15 mg/day		 Male:  17 – 80 µmol/day
Female: 10 – 52 µmol/day
Lactate dehydrogenase LDH (serum) isoenzymes

top of page

 LD-1: 14-30% of total
LD-2: 29-48% of total
LD-3: 16-25% of total
LD-4: 8-12% of total
LD-5: 6-20% of total		  
Lactate Dehydrogenase, Total:

top of page

 0 up to 30 days: 200-465 U/L
1-17 months: 200-450 U/L
18 mo-10 yr: 165-430 U/L
11-16 years: 127-287 U/L
> 17 yrs: 105-230 U/L

Alt: > 17yr: </= 270 U/L

 Alt: > 17yr: </= 4.5 µkat/L
Lactic acid (plasma (venous))
top of page 		9 – 16 mg/dL 1.0 – 1.8 mmol/L
Lead (blood)

top of page

 < 25 µg/dL < 1.21 µmol/L
Lipase (serum)
top of page		 7 – 60 U/L 0.12 – 1.00 µkat/L
Low density lipoprotein (LDL) cholesterol (serum)

top of page

 Desirable: < 130 mg/dL
Borderline-high: 130 -159mg/dL
High: >/= 160 mg/dL		 Desirable: < 3.36 mmol/L
Borderline-high:
        3.36 – 4.11 mmol/L
High: >/= 4.14 mmol/L
Luteinizing hormone (LH) serum

top of page
Age  Male
(IU/L) 		 Female
(IU/L) 
0-23 mo  0.5-1.9  0.0-0.5 
2-10 y  0.0-0.5  0.0-0.5 
11-20 y  0.5-5.3  0.5-9.0 
20-70 y  1.5-9.3  0.0-76.3 
70-100 y  3.1-34.6  5.0-52.3 
    Follicular: 2.4 – 12.6
    Midcycle: 14 – 95.6 
    Luteal: 1.0 – 11.4 
    Pregnant: 0.0-1.5 
    Postmenopausal: 7.7 – 58.5 
    Contraceptives: 0.7-5.6 
Tanner Stage 
I  0.0-1.0 IU/L 0.0-9.3 IU/L
II  0.0-3.6 IU/L 0.0-16.0 IU/L
III  0.2-6.4 IU/L 0.0-23.0 IU/L
IV & V  0.9-8.3 IU/L  0.0-19.1 IU/L
Lymphocyte surface markers (T cell)  Blood

top of page
Components Age:
0-11 mo		 Age:
12-23mo		 Age:
> 2 yr
% CD4  (Helper T-cells)
Absolute CD4		 38-62%
1580-4850		 31-54%
1020-3600		 32-62%
381-1469
% CD45RA (Naive helper T-cells)
Absolute CD45RA		 15-70%
200-3400		 15-70%
200-3400		 3-38%
44-869
% CD45RO
(Memory helper T-cells)
Absolute CD45RO		 5-30%
50-1500		 5-30%
50-1500		 16-46%
92-1040
% CD8 (Suppressor T-cells)
Absolute CD8		 16-34%
680-2470		 16-38%
570-2230		 12-45%
196-1060
CD4: CD8 ratio 1.17-6.62 1.17-6.62 0.80-5.00
% CD3 (Total T-cells)
Absolute CD3		 58-85%
2170-6500		 53-81%
1460-5440		 58-87%
684-2170
% CD19 (B-cells)
Absolute CD19		 11-45%
430-3300		 11-45%
430-3300		 5-23%
116-613
% NK-cells
Absolute NK-cells		 3-19%
80-340		 3-19%
80-340		 4-27%
76-570
  Age  95% CI 
Percentage (min/max) Cells/mm3 (min/max)
Minimum  Minimum 
CD3  Neonates  28 – 76 600 -5000
  1 wk – 2 mo  60 – 85 2300 -7000
  2-5 mo  48 -75 2300 -6500
  5-9 mo  50 -77 2400 -6900
  9-15 mo  54 -76 1600 -6700
  15-24 mo  39 -73 1400 -8000
  2-5 y  43 -76 900 -4500
  5-10 y  55 -78 700 -4200
  10-16 y  52 -78 800 -3500
  Adults  58 -86 622 -2402
CD3+CD4+  Neonates  17 -52 400 -3500
  1 wk – 2 mo  41 -68 1700 -5300
  2-5 mo  33 -58 1500 -5000
  5-9 mo  33 -58 1400 -5100
  9-15 mo  31 -54 1000 -4600
  15-24 mo  25 -50 900 -5500
  2-5 y  23 -48 500 -2400
  5-10 y  27 -53 300 -2000
  10-16 y  25 -48 400 -2100
  Adults  31 -59 359 -1519
CD3+CD8+  Neonates  10 -41 200 -1900
  1 wk – 2 mo  9 -23 400 -1700
  2-5 mo  11 -25 500 -1600
  5-9 mo  13 -26 600 -2200
  9-15 mo  12 -28 400 -2100
  15-24 mo  11 -32 400 -2300
  2-5 y  14 -33 300 -1600
  5-10 y  19 -34 300 -1800
  10-16 y  9 -35 200 -1200
  Adults  12 -36 109 -897
T4:T8 ratio  Adults  0.92 -3.72  
CD19+  Neonates  5 -22 40 -1100
  1 wk – 2 mo  4 -26 600 -1900
  2-5 mo  14 -39 600 -3000
  5-9 mo  13 -35 700 -2500
  9-15 mo  15 -39 600 -2700
  15-24 mo  17 -41 600 -3100
  2-5 y  14 -44 200 -2100
  5-10 y  10 -31 200 -1600
  10-16 y  8 -24 200 -600
  Adults  3 -25 12 -645
CD3–CD56+  Neonates  6 -58 100 -1900
  1 wk – 2 mo  3 -23 200 -1400
  2-5 mo  2 -14 100 -1300
  5-9 mo  2 -13 100 -1000
  9-15 mo  3 -17 200 -1200
  15-24 mo  3 -16 100 -1400
  2-5 y  4 -23 100 -1000
  5-10 y  4 -26 90 -900
  10-16 y  6 -27 70 -1200
  Adults  1 -19 24 -406
Pediatric reference intervals are from Comans-Bitter WM, et al, “Immunophenotyping of Blood Lymphocytes in Childhood,” J Pediatrics, 1997, 130:388-93

Disclaimer

The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user’s use of or reliance upon this material.PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read the disclaimer